NASDAQ$APLT
Applied Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2023.
Applied Therapeutics reported its Q1 2023 financial results, highlighting the long-term clinical benefit of Govorestat in the ACTION-Galactosemia Kids Trial and a strengthened balance sheet with a $30 million private placement of equity. Phase 3 INSPIRE trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy are on track for data in 2023.
- Demonstrated long-term clinical benefit of Govorestat in ACTION-Galactosemia Kids Trial.
- Strengthened balance sheet with $30 million private placement of equity.
- Phase 3 INSPIRE Trial of Govorestat in SORD Deficiency on track for data in 2023.
- ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on track for data in 2023.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$10.7M
Forward guidance
The company anticipates potential approval of govorestat for Galactosemia later this year and is excited about upcoming data readouts in SORD Deficiency and Diabetic Cardiomyopathy.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2023
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro